Market LIVE
Published markets; coverage varies by country
Product profile · United States

AMBELVIST

 ·  Patent Litigation & Settlement History ↓

IngredientGADOQUATRANE
Application typeNDA
Application219627
Product002
Dosage formSOLUTION
RouteINTRAVENOUS
Strength1.93425GM/7.5ML (257.9MG/ML)
Approval date2026-06-12
Marketing statusPrescription
Status event—
ApplicantBAYER HEALTHCARE
Product source

Current GenericRadar decision

Year2026
SelectionEXCLUDED
ReviewFINAL
Anchor typeAPPROVAL_DATE
Anchor date2026-06-12
Patent anchor2036-05-30
Exclusivity anchor2031-06-12
Protection date2040-05-19
First Final ANDA—
Status event—

GNR judgment: EXCLUDED. Reference year: 2026. Anchor type: APPROVAL_DATE. Patent anchor: 2036-05-30. Exclusivity anchor: 2031-06-12. Anchor date: 2026-06-12. Patent tail: yes. Exclusivity tail: no. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
101372092036-05-30DS/U U-4424YNTRUE_DS
| B1C03 issued-claim review2026-10-15: TRUE_DS
———
101372092036-05-30ORANGE_BOOK U-4424YNTRUE_DS
English description not available.
———
107226012036-05-30DS/U U-4424YNTRUE_DS
| B1C03 issued-claim review2026-10-15: TRUE_DS
———
107226012036-05-30ORANGE_BOOK U-4424YNTRUE_DS
English description not available.
———
114912452036-05-30DS —YNTRUE_DS
| B1C03 issued-claim review2026-10-15: TRUE_DS
———
114912452036-05-30ORANGE_BOOK —YNTRUE_DS
English description not available.
———
124786962036-05-30DS —YNTRUE_DS
| B1C03 issued-claim review2026-10-15: TRUE_DS
———
124786962036-05-30ORANGE_BOOK —YNTRUE_DS
English description not available.
———
123035732039-11-21DP —NNDP
| B1C03 issued-claim review2026-10-15: DP
———
123035732039-11-21ORANGE_BOOK —NNDP
English description not available.
———
119446902040-05-19DP —NNDP
| B1C03 issued-claim review2026-10-15: DP
———
119446902040-05-19ORANGE_BOOK —NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2026-06-122031-06-12English description not available.YY2031-06-12—Source
NCE2026-06-122031-06-12English description not available.YY2031-06-12
NCE
Full coverage date: 2031-06-12
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (8)
TypeDateRoleBasisSource
PATENT2036-05-30HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2036-05-30HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2036-05-30HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2036-05-30HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2039-11-21HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2040-05-19HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY—HISTORICAL_CONTEXTEnglish description not available.Source
REGULATORY_STATUS2026-06-12TERMINAL_STATUSEnglish description not available.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.